Please assess the completion status of the following clinical trial:

Trial Title: Trial of Cytisine in Adult Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects, age ≥ 18 years.~2. Current daily cigarette smokers (averaging ≥ 10 cigarettes per day upon completing a 7-day screening diary) and who intend to quit smoking.~3. Expired air carbon monoxide (CO) ≥ 10 parts per million (ppm).~4. Failed at least one previous attempt to stop smoking with or without therapeutic support.~5. Willing to initiate study treatment on the day after randomization and set a quit date that is 5-7 days after starting treatment.~6. Willing to actively participate in the study's smoking cessation behavioral support provided throughout the study.~7. Able to fully understand all study requirements, willing to participate, comply with dosing schedule, and sign the Informed Consent Form.~Exclusion Criteria:~1. Known hypersensitivity to cytisine or any of the excipients.~2. Positive urinary drugs of abuse screen, determined within 28 days before the first dose of cytisine.~3. Clinically significant abnormal serum chemistry or hematology values within 28 days of randomization (i.e. requiring treatment).~4. Clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined after minimum of 5 minutes in supine position within 28 days of randomization (i.e. requiring treatment or further assessment).~5. Body mass index (BMI) classification for being underweight (\< 18.5 kg/m\^2) or having ≥ Class 2 obesity (≥ 35 kg/m\^2).~6. Recent history (within 3 months) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.~7. Current uncontrolled hypertension (blood pressure ≥ 160/100 mmHg).~8. Documented diagnosis of schizophrenia or bipolar psychiatric illness; currently psychotic; having suicidal ideation (Suicide Behaviors Questionnaire-Revised \[SBQ-R\] score ≥ 7); or current symptoms of moderate to severe depression (Hospital Anxiety and Depression Scale \[HADS\] score ≥ 11).~9. Renal impairment defined as a creatinine clearance (CrCl) \< 60 mL/min (estimated with the Cockroft-Gault equation) or hepatic impairment defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2.0 times the upper limit of normal (ULN).~10. Women who are pregnant or breast-feeding.~11. Male or Female subjects of child bearing potential who do not agree to use acceptable methods of birth control during the study treatment period.~12. Participation in a clinical study with an investigational drug within 4 weeks of randomization.~13. Treatment with other smoking cessation medications (bupropion, varenicline, nortriptyline, or any nicotine replacement therapy \[NRT\]) within 4 weeks of randomization or planned use of these other smoking cessation medications during the study.~14. Use within 2 weeks of randomization or planned use during the study of non-cigarette nicotine products (e-cigarettes, pipe tobacco, cigars, snuff, chewing tobacco, hookah) or marijuana vaping or smoking.~15. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.5 mg Cytisine, Commercial Schedule (Type: EXPERIMENTAL): 1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
- 3.0 mg Cytisine, Commercial Schedule (Type: EXPERIMENTAL): 3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
- Placebo, Commercial Schedule (Type: PLACEBO_COMPARATOR): Placebo tablets using the commercial 25-day titration schedule + behavioral support
- 1.5 mg Cytisine, TID Schedule (Type: EXPERIMENTAL): 1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support
- 3.0 mg Cytisine, TID Schedule (Type: EXPERIMENTAL): 3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support
- Placebo, TID Schedule (Type: PLACEBO_COMPARATOR): Placebo tablets for 25 days using a simplified TID schedule + behavioral support

Based on this trial design, predict the completion outcome and termination type (if applicable).